Organ regeneration is a rapidly advancing field in medical science, and eGenesis, a biotechnology company based in Boston, MA, is at the forefront of this exciting research. By harnessing the power of gene editing and stem cell technology, eGenesis aims to revolutionize the way we approach organ transplantation.
Traditionally, organ transplantation has relied on finding a suitable donor and ensuring compatibility between the donor and recipient. However, this process is often hindered by a shortage of donor organs and the risk of rejection by the recipient's immune system. eGenesis seeks to overcome these challenges by developing organs that are genetically compatible with the recipient, thereby eliminating the need for immunosuppressive drugs.
One of the key technologies being employed by eGenesis is CRISPR-Cas9, a revolutionary gene editing tool. By precisely modifying the genes of pig embryos, eGenesis is able to create pigs with organs that are less likely to be rejected by the human immune system. These genetically modified pigs, known as xenotransplantation donors, have the potential to provide a renewable source of organs for transplantation.
For example, eGenesis has successfully used CRISPR-Cas9 to modify the pig genome and remove a specific gene responsible for triggering an immune response in humans. This breakthrough has significantly reduced the risk of rejection and brought us closer to the reality of using pig organs in human transplantation.
Furthermore, eGenesis is also exploring the use of induced pluripotent stem cells (iPSCs) in organ regeneration. iPSCs are adult cells that have been reprogrammed to behave like embryonic stem cells, capable of differentiating into any cell type in the body. By coaxing iPSCs to develop into specific organ cells, eGenesis aims to create functional organs for transplantation.
- eGenesis Official Website
- CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells
- Generation of α1,3-galactosyltransferase knocked-out pigs using CRISPR-Cas9
101 Cambridgepark Dr suite 200, Cambridge, MA 02140, USA